Patents by Inventor Enrique Pérez Payá
Enrique Pérez Payá has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10544083Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: GrantFiled: February 8, 2018Date of Patent: January 28, 2020Assignee: Universitat de ValènciaInventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
-
Publication number: 20180179139Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: ApplicationFiled: February 8, 2018Publication date: June 28, 2018Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
-
Publication number: 20160083327Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: ApplicationFiled: November 18, 2015Publication date: March 24, 2016Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
-
Patent number: 9199936Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: GrantFiled: October 25, 2013Date of Patent: December 1, 2015Assignee: Fibrostatin Sociedad LimitadaInventors: Juan Saus, Santos Fustero, Juan F Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
-
Patent number: 9040701Abstract: Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis.Type: GrantFiled: July 29, 2010Date of Patent: May 26, 2015Assignee: LABORATORIOS SALVAT, S.A.Inventors: Ángel Messeguer Peypoch, Alejandra Moure Fernández, Daniel González Pinacho, Isabel Masip Masip, Enrique Pérez Payá, Natividad García Villar, Ester Monlleó Mas, Juanlo Catena Ruiz
-
Publication number: 20140080852Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: ApplicationFiled: October 25, 2013Publication date: March 20, 2014Applicant: FIBROSTATIN, S.L.Inventors: Juan Saus, Santos Fustero, Juan F Sanz-Cervera, Enrique Pérez-Payá, Raül Blasco, Francisco Revert-Ros, Fernando Revert
-
Patent number: 8586776Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: GrantFiled: November 5, 2010Date of Patent: November 19, 2013Assignee: FibroStatin, S.L.Inventors: Juan Saus, Santos Fustero, Juan F. Sanz-Cervera, Enrique Perez-Paya, Raul Blasco, Francisco Revert-Ros, Fernando Revert
-
Publication number: 20130143825Abstract: Compounds to be used in the treatment of diseases based on the expression of toxic transcripts. The present invention relates to peptide molecules, specifically hexapeptides, designed for the prevention and/or treatment of diseases the etiology whereof is based on the presence of toxic transcripts that comprise CUG, CCUG, CGG, CAG and AAG repeats, preferably: DM1 SCA8, DM2, FXTAS, HD and FA.Type: ApplicationFiled: March 9, 2011Publication date: June 6, 2013Applicants: UNIVERSITAT DE VALENCIA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS, FUNDACIÓN DE LA COMUNIDAD VALENCIANA CENTRO DE INVESTIGACION PRINCIPE FELIPEInventors: Ruben Darío Artero Allepuz, Amparo Garcia López, Maria Del Mar Orzáez Calatayud, Maria Beatriz Llamusí Troisi, Enrique Pérez Payá, Manuel Pérez Alonso
-
Publication number: 20120122868Abstract: Derivatives of 2,5-piperazinedione of formula (I) are apoptotic peptidase activating factor 1 (Apaf-1) inhibitors, therefore they are useful as active pharmaceutical ingredients for the prophylaxis and/or treatment of a pathological and/or physiological condition associated with an increase of apoptosis.Type: ApplicationFiled: July 29, 2010Publication date: May 17, 2012Applicant: LABORATORIOS SALVAT, S.A.Inventors: Ángel Messeguer Pyepoch, Alejandra Moure Fernández, Daniel Gonzáles Pinacho, Isabel Masip Masip, Enrique Pérez Payá, Natividad García, Ester Monlleó Mas, Juanlo Catena Ruiz
-
Patent number: 8110545Abstract: The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1).Type: GrantFiled: December 29, 2006Date of Patent: February 7, 2012Assignees: Universidad Del Pais Vasco, Universidad de ValenciaInventors: Jose Luis Nieva Escandon, Maria Jose Gomara Elena, Maier Lorizate Nogales, Nerea Huarte Arrayago, Ismael Mingarro Munoz, Enrique Perez Paya
-
Publication number: 20110105545Abstract: Disclosed are compounds of formula: that inhibiting GPBP activity, making them useful as therapeutics in antibody-mediated disorders, drug-resistant cancer, inflammation, protein misfolding and ER stress-mediated disorders, and aberrant apoptosis.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Applicant: FIBROSTATIN, S.L.Inventors: JUAN SAUS, SANTOS FUSTERO, JUAN F. SANZ-CERVERA, ENRIQUE PEREZ-PAYA, RAUL BLASCO, FRANCISCO REVERT-ROS, FERNANDO REVERT
-
Publication number: 20100197606Abstract: The invention relates to non-proteolysable oligopeptides that inhibit glycoprotein 41 of the AIDS virus. More specifically, the invention relates to the identification of oligopeptides, particularly hexapeptides, (D), (L) or mixed, preferably D-hexapeptides, which inhibit the binding of a retrovirus to a target cell, thereby providing novel therapies against infection from the human immunodeficiency virus (HIV). The invention also relates to the use of said D-hexapeptides in the form of single components or complex mixtures as prophylactic or therapeutic agents for retroviral infections, especially human immunodeficiency virus type 1 (HIV-1).Type: ApplicationFiled: December 29, 2006Publication date: August 5, 2010Inventors: José Luis Nieva Escandón, Maria José Gómara Elena, Maier Lorizate Nogales, Nerea Huarte Arrayago, Ismael Mingarro Munoz, Enrique Pérez Paya
-
Publication number: 20090298781Abstract: The present invention relates to compounds of formula (I) as well as to drug conjugates based on compounds of formula (I) acting as apoptosis inhibitors, as well as to processes for their preparation, to pharmaceutical compositions containing them and their use in medicine.Type: ApplicationFiled: November 22, 2006Publication date: December 3, 2009Applicant: CONSEJO SUPERIOR DEInventors: Enrique Perez Payá, Maria Jesús Vicent Docon, Mar Orzaez Calatayud, Laura Mondragon Martinez, Angél Messeguer Paypoch, Alejadra Moure Fernandez, Gloria Sanclimens Perez De Rozas, Gema Malet Engra
-
Patent number: 7473679Abstract: The peptide has a sequence of 3 to 30 adjacent amino acids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain said peptide and optionally one or more peptides from the carboxyl end of SNAP-25. The compositions are suitable for the treatment of facial wrinkles, asymmetry and pathological neuronal exocytosis-mediated pathological disorders and alterations.Type: GrantFiled: January 9, 2006Date of Patent: January 6, 2009Assignee: Lipotec, S.A.Inventors: Ma Clara Blanes Mira, Ma Mercedes Llobregat Hernandez, Ana Isabel Gil Tebar, Gregorio Joaquin Fernandez Ballester, Rosa Ma Planell Cases, Antonio Vicente Ferrer Montiel, Salvador Viniegra Bover, Luis Miguel Gutierrez Perez, Teresa Carbonell Castello, Enrique Perez Paya
-
Patent number: 7015192Abstract: The peptide has a sequence of 3 to 30 adjacent amino acids from the amino end of protein SNAP-25 and is useful as neuronal exocytosis inhibitor. The cosmetic and pharmaceutical compositions contain said peptide and optionally one or more peptides from the carboxyl end of SNAP-25. Said compositions are suitable for the treatment of facial wrinkles and asymmetry and pathological neuronal exocytosis-mediated pathological disorders and alterations.Type: GrantFiled: February 18, 2000Date of Patent: March 21, 2006Assignee: Lipotec, S.A.Inventors: Ma Clara Blaines Mira, Ma Mercedes Llobregat Hernandez, Ana Isabel Gil Tebar, Gregorio Joaquin Fernandez Ballester, Rosa Ma Planell Cases, Antonio Vicente Ferrer Montiel, Salvador Viniegra Bover, Luis Miguel Gutierrez Perez, Teresa Carbonell Castello, Enrique Perez Paya
-
Patent number: 6992064Abstract: N-alkylglycine trimeres, their stereoisomers, racemic mixtures and salts of formula (I) below, where R1, R2 and R3, independent of one another, are chosen from amongst cyclopropyl, sec-butyl, 2-methoxyethyl, 3-methylbutyl, cyclohexyl, 2-(N-pyrrolidinyl)ethyl, 2-(methylcarbonylamine)ethyl, 3-(2-oxo-N-pyrrolidinyl)propyl, 2-(2-pyridyl)ethyl, 2-phenylethyl, 1-(2-tetrahydrofuryl)methyl, 2-(N-imidazolyl) ethyl, 2-(4-methoxyphenyl)ethyl, 2-(3,4-dimethoxyphenyl)ethyl, 2-(2,4-dichlorophenyl)ethyl, 2-[2-(N-methyl)pyrrolidinyl]ethyl, 2-(4-aminosulfonylphenyl)ethyl, 2-(morpholine)ethyl, 3-(N,N-diethylamine)propyl, 3,3-diphenyipropyl, 3-(N,N-dimethylamine)propyl, and 2-(N,N-diethylamine)ethyl, their stereoisomeric forms and their mixtures, which are capable of blocking L-glutamate receptors and are useful for treating disorders mediated by neurodegeneration, for example, cerebral ischemia, cerebrovascular accident, migraine, depression, Huntington, Parkinson, Alzheimer, senile dementia, epilepsy and multiple and amyotropType: GrantFiled: October 5, 2001Date of Patent: January 31, 2006Assignee: Diverdrugs, S.L.Inventors: Vicente Felipo Orts, Carmen Montoliu Felix, Antonio Ferrer Montiel, Rosa Planells Cases, Jaime M. Merino Fernandez, Enrique Perez Paya, Francisco Sanchez Baeza, Merc Humet, Angel Messeguer Peypoch
-
Publication number: 20040029811Abstract: The N-alkylglycine trimeres (I), where R1, R2 and R3, independent of one another, are chosen from amongst cyclopropyl, sec-butyl, 2-metoxyethyl, 3-methylbutyl, cyclohexyl, 2-(N-pyrrolidinyl)ethyl, 2-(methylcarbonylamine)ethyl, 3-(2-oxo-N-pyrrolidinyl)propyl, 2-(2-pyridyl)ethyl, phenylethyl, 1-(2-tetrahydrofuryl)methyl, 2-(N-imidazolyl) ethyl, 2-(4-metoxyphenyl) ethyl, 2-(3,4-dimetoxyphenyl) ethyl, 2-(2,4-dichlorophenyl) ethtyl, 2-[2-(N-methyl) pyrrolidinyl] ethyl, 2-(4-aminosulfonylphenyl) ethyl, 2-(morpholine) ethyl, 3-(N,N-diethylamine) propyl, 3,3-diphenylpropyl, 3-(N,N-dimethylamine) propyl, and 2-(N,N-diethylamine) ethyl, their stereoisomeric forms and their mixtures, which are capable of blocking L-glutamate receptors and are useful for treating disorders mediated by said receptors.Type: ApplicationFiled: August 21, 2003Publication date: February 12, 2004Inventors: Vicente Felipo Orts, Carmen Montoliu Felix, Antonio Ferrer Montiel, Rosa Planells Cases, Jaime M. Merino Fernandez, Enrique Perez Paya, Francisco Sanchez Baeza, Merc Humet, Angel Messeguer Peypoch
-
Patent number: 5840697Abstract: The present invention relates to novel family of peptides which inhibit calmodulin and which have the general structure Ac-A1-B2-C3-D4-E5-F6-NH.sub.2, (SEQ ID No. 1), wherein A1 is (D)Leu or Leu, B2 is (D)Gln, Gln, (D)Trp, or Trp, C3 is (D)Arg, Arg, (D)Ile, or Ile, D4 is (D)Ile, Ile, (D)His, or His, E5 is (D)Leu, Leu, (D)His, or His, and F6 is (D)Trp, Trp, (D)Arg, or Arg. The novel peptides can be used to inhibit the activity of calmodulin. In addition, the present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a calmodulin-inhibitor peptide. These compositions can be used to treat calmodulin related disorders.Type: GrantFiled: June 6, 1996Date of Patent: November 24, 1998Assignee: Torrey Pines Institute for Molecular StudiesInventors: Sylvie E. Blondelle, Richard A. Houghten, Enrique Perez-Paya
-
Patent number: 5814470Abstract: Sets and libraries of sets of polypeptides that are related in sequence to melittin are disclosed that have antimicrobial, hemolytic and hydrolytically catalytic activities, as are processes for making and using the same. A contemplated set is a mixture of equimolar amounts of a polypeptide of SEQ ID NO:2, and more preferably SEQ ID NO:3.Type: GrantFiled: July 7, 1997Date of Patent: September 29, 1998Assignee: Torrey Pines Institute for Molecular StudiesInventors: Sylvie Blondelle, Richard A. Houghten, Enrique Perez-Paya
-
Patent number: 5645996Abstract: Sets and libraries of sets of polypeptides that are related in sequence to melittin are disclosed that have antimicrobial, hemolytic and hydrolyrically catalytic activities, as are processes for making and using the same. A contemplated set is a mixture of equimolar amounts of a polypeptide of SEQ ID NO:2, and more preferably SEQ ID NO:3.Type: GrantFiled: August 24, 1994Date of Patent: July 8, 1997Assignee: Torrey Pines Institute for Molecular StudiesInventors: Sylvie Blondelle, Richard A. Houghten, Enrique Perez-Paya